Everest Biotech awards $100,000 antibody grant
Everest Biotech is delighted to announce the winners of its inaugural Antibody Creation Grant. Worth up to $100,000, the funding was offered to research labs around the world. The winners are:
- Professor Gillian Griffith (University of Cambridge, UK): To characterize and investigate the less known components involved in the cytotoxic T cell function.
- Assistant Professor Melinda Larsen (University at Albany-SUNY, USA): To fully investigate and map the presence and localization of proteins involved in the development of salivary glands, leading to a deeper understanding of Sjogren’s syndrome.
- Assistant Professor Bernard Lassegue (Emory University, USA): Looking at the organization and regulation of the components of NADP-oxidases.
- Associate Professor Michael Tuvim (University of Texas, USA): Focusing on the regulation of mucus formation in airways. Everest Biotech and Dr Tuvim will work closely together to generate the required reagents, thus dramatically speeding up the research in this area.
- Professor Michihiro Igarashi (Niigata University, Japan): Investigating the components of growth cones in adult brains. The proteomic approach has identified a number of proteins involved in higher brain functions through these growth cones. Everest Biotech antibodies will be used to further investigate and characterize the mechanisms of neuronal organization and repair, therefore, leading to groundbreaking neuroscience.
Everest Biotech CSO, Dr Jan Voskuil, commented: “The response to the grant was phenomenal, with applicants from all over the world competing for the $100,000. Everest Biotech’s scientific board had a very hard job in picking a single winner, such was the calibre of entries. In the end, we decided to split the prize across five groups that we felt would benefit most from the award, and we congratulate the winners. Everest Biotech is delighted and excited about our contribution to these projects. It is accepted that antigen affinity-purified peptide antibodies complement and often outperform existing monoclonal antibodies. We hope that the variety of winning projects will maximize the impact Everest Biotech will have on the progress in medical science.”
Other news from the department science
These products might interest you
Micro-Dx™ CE IVD by Molzym
Fully automated from sample to PCR analysis
Rapid identification of bacteria and fungi without time-consuming cultivation
DNA-free Taq Polymerases and Mastermixes by Molzym
DNA-free reagents for unrivalled sensitivity in molecular biology
Purity that makes the difference
DNA/RNA Shield™ SafeCollect Collection Kits by Zymo Research
Sample collection devices for simple & safe at-home testing
Best user experience for secure self-collection
Recombumin® Elite by Sartorius
ICHQ7 cGMP-compliant albumin for biotechnological applications
Increase consistency and safety for gene therapies and vaccines
CellGenix® Growth Factors and Cytokines by Sartorius
Recombinant growth factors without animal products
Optimised cell culture for T cells and MSCs in gene therapy
Greener Alternative Products by Merck Life Science
Sustainable laboratory products for environmentally conscious research
Over 2,500 ecological alternatives to reduce your laboratory footprint
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous